BofA Downgrades Chemed Corporation (CHE) to Cautious Feb 26, 2026

Bank of America Securities downgraded Chemed Corporation (CHE) to Cautious on February 26, 2026. The CHE analyst rating change follows a weaker Roto-Rooter EBITDA and a 2026 EBITDA guide below Street expectations. BofA also cut its price target to $450, citing the Q4 miss and softer 2026 outlook. This single notable downgrade landed after Chemed reported results and prompted immediate market reassessment.

CHE analyst rating: Downgrade details from Bank of America Securities

Bank of America issued the downgrade to Cautious on February 26, 2026 after Chemed’s Q4 results missed EBITDA forecasts. The note highlighted weaker Roto-Rooter performance and 2026 EBITDA guidance roughly 6% below expectations source.

CHE analyst rating and price target change impact

BofA cut its price target to $450, per coverage summarized on Seeking Alpha source. The downgrade and target cut tied directly to the earnings miss and guidance, shifting near-term investor expectations.

CHE analyst rating: Short-term stock reaction and market moves

Chemed stock hit a 52-week low after the results and downgrade, moving 20.58% and about $79.92 from recent levels. The downgrade accelerated selling as traders priced in weaker Roto-Rooter cash flow.

CHE analyst rating implications for investors and strategy

A Cautious rating signals a more guarded stance on near-term upside, urging investors to weigh earnings risk over long-term operations. Investors should reassess exposure to Roto-Rooter cash flow and compare valuation to peers before trading on this single downgrade.

CHE analyst rating in historical context of coverage

This Feb 26, 2026 action is the only prominent rating change recorded in our recent feed for Chemed. Historically, Chemed draws coverage from major brokers who focus on Roto-Rooter and hospice cash flow trends, so BofA’s move carries outsized attention.

Meyka AI market analysis and stock grade for CHE analyst rating

Meyka AI rates CHE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Bank of America’s February 26, 2026 downgrade of Chemed to Cautious and its $450 price target cut reflect a meaningful shift after a Q4 EBITDA miss. The CHE analyst rating change sharpens investor focus on Roto-Rooter execution and 2026 guidance. For traders, the downgrade increased short-term volatility and prompted multiple exits.

Longer term, the downgrade does not erase Chemed’s underlying business strengths, but it does lower near-term conviction. Investors should monitor subsequent earnings, operational updates from Roto-Rooter, and any follow-up guidance revisions before increasing exposure. Use Meyka AI’s real-time tools for ongoing coverage and to compare Chemed versus peers in the sector.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.